Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597889 | 0.87 | CCR5 (0.57) | CCR5CXCR4POLBDRD2SIGMAR1 | |
| SCHEMBL19658841 | 0.87 | TACR2 (0.55) | CCR5CXCR4POLBDRD2SIGMAR1 | |
| SCHEMBL19658975 | 0.85 | CCR5 (0.58) | CCR5CXCR4POLBDRD2SIGMAR1 | |
| SCHEMBL19658607 | 0.83 | CXCR4 (0.56) | CXCR4POLBDRD2ALDH1A1ATM | |
| SCHEMBL19652128 | 0.82 | CCR5 (0.48) | CCR5DRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL17753689 | 0.81 | CXCR4 (0.63) | CXCR4POLBSIGMAR1ALDH1A1ATM | |
| SCHEMBL28534607 | 0.80 | CXCR4 (0.58) | CXCR4POLBSIGMAR1ALDH1A1ATM | |
| SCHEMBL19652261 | 0.80 | CCR5 (0.55) | CCR5CXCR4DRD2SIGMAR1HTR2A | |
| SCHEMBL29321598 | 0.79 | SIGMAR1 (0.57) | CCR5DRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL29321604 | 0.79 | SIGMAR1 (0.57) | CCR5DRD2SIGMAR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CCR5 1178/4885CXCR4 796/4885POLB 1307/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CCR5 1178/4885CXCR4 796/4885POLB 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.